[미국특허]
LOX and LOXL2 inhibitors and uses thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07K-016/00
C12P-021/08
출원번호
US-0185050
(2008-08-01)
등록번호
US-8461303
(2013-06-11)
발명자
/ 주소
Smith, Victoria
Ogg, Scott
Van Vlasselaer, Peter
Barry, Vivian E.
Marshall, Derek
Holzer, Alison Kay
Rodriguez, Hector
Oyasu, Miho
McCauley, Scott Alan
Garcia, Carlos Aurelio
Biermann, Donna Hiroko Tokuoka
출원인 / 주소
Gilead Biologics, Inc.
대리인 / 주소
Morrison & Foerster LLP
인용정보
피인용 횟수 :
8인용 특허 :
60
초록▼
The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and tre
The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.
대표청구항▼
1. An isolated antibody or antigen binding fragment thereof, comprising a heavy chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 25, 26, 27, or 28, and a light chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 30, 31, or 32, wherein the
1. An isolated antibody or antigen binding fragment thereof, comprising a heavy chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 25, 26, 27, or 28, and a light chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 30, 31, or 32, wherein the isolated antibody or antigen binding fragment thereof specifically binds a lysyl oxidase-like 2 (LOXL2) protein. 2. An isolated antibody or antigen binding fragment thereof, comprising a heavy chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 25, 26, 27, or 28, wherein the isolated antibody or antigen binding fragment thereof specifically binds a lysyl oxidase-like 2(LOXL2) protein. 3. An isolated antibody or antigen binding fragment thereof, comprising a light chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 30, 31, or 32, wherein the isolated antibody or antigen binding fragment thereof specifically binds a lysyl oxidase-like 2 (LOXL2) protein. 4. An isolated antibody or antigen binding fragment thereof, comprising the complementarity determining regions (CDRs), CDR1, CDR2, and CDR3, of a heavy chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 25, 26, 27, or 28, and the CDRs, CDR1, CDR2, and CDR3, of a light chain variable region comprising the amino acid sequence set forth as SEQ ID NO: 30, 31, or 32, wherein the isolated antibody or antigen binding fragment thereof specifically binds a lysyl oxidase-like 2(LOXL2) protein. 5. The isolated antibody or antigen binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 25. 6. The isolated antibody or antigen binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 26. 7. The isolated antibody or antigen binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 27. 8. The isolated antibody or antigen binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 28. 9. The isolated antibody or antigen binding fragment thereof of claim 1, wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 30. 10. The isolated antibody or antigen binding fragment thereof of claim 1, wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 31. 11. The isolated antibody or antigen binding fragment thereof of claim 1, wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 32. 12. The isolated antibody or antigen binding fragment thereof of claim 1, wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO:27 and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO:31. 13. The isolated antibody or antigen binding fragment thereof of claim 2, wherein, the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 25. 14. The isolated antibody or antigen binding fragment thereof of claim 2, wherein, the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 26. 15. The isolated antibody or antigen binding fragment thereof of claim 2, wherein, the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 27. 16. The isolated antibody or antigen binding fragment thereof of claim 2, wherein, the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 28. 17. The isolated antibody or antigen binding fragment thereof of claim 3, wherein, the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 30. 18. The isolated antibody or antigen binding fragment thereof of claim 3, wherein, the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 31. 19. The isolated antibody or antigen binding fragment thereof of claim 3, wherein, the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 32. 20. The isolated antibody or antigen binding fragment thereof of claim 1, wherein the antibody or fragment is labeled with a detectable label, a therapeutic agent or both. 21. The isolated antibody or antigen binding fragment thereof of claim 1, wherein the antibody or fragment is a Fv, a scFv, a Fab, a F(ab')2, or monoclonal. 22. The isolated antibody or antigen binding fragment thereof of claim 4, wherein the CDR1, CDR2, and CDR3 of the heavy chain variable region comprise the amino acid sequences set forth as SEQ ID NOs: 41, 42, and 70, respectively, and the CDR1, CDR2, and CDR3of the light chain variable region comprise the amino acid sequences set forth as SEQ ID NOs: 57, 58, and 59, respectively. 23. The isolated antibody or antigen binding fragment thereof of claim 1, wherein the antibody or fragment is labeled with a therapeutic agent. 24. The isolated antibody or antigen binding fragment thereof of claim 2, wherein the antibody or fragment is labeled with a detectable label, a therapeutic agent or both. 25. The isolated antibody or antigen binding fragment thereof of claim 2, wherein the antibody or fragment is labeled with a therapeutic agent. 26. The isolated antibody or antigen binding fragment thereof of claim 2, wherein the antibody or fragment is a Fv, a scFv, a Fab, a F(ab')2, or monoclonal. 27. The isolated antibody or antigen binding fragment thereof of claim 3, wherein the antibody or fragment is labeled with a detectable label, a therapeutic agent or both. 28. The isolated antibody or antigen binding fragment thereof of claim 3, wherein the antibody or fragment is labeled with a therapeutic agent. 29. The isolated antibody or antigen binding fragment thereof of claim 3, wherein the antibody or fragment is a Fv, a scFv, a Fab, a F(ab')2, or monoclonal. 30. The isolated antibody or antigen binding fragment thereof of claim 4, wherein the antibody or fragment is humanized.
Kagan Herbert M. (Arlington MA) Gacheru Stephen N. (Worcester MA), Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in-situ using adjacently positioned diamin.
Garcia Fernando S. (Eden Prairie MN) Ginnow-Merkert Hartmut (Eden Prairie MN) Anderson Paul J. (Eden Prairie MN) Hudson Bertram J. (Eden Prairie MN), Glucose medical monitoring system.
Wands Jack R. (Waban MA) Zurawski ; Jr. Vincent R. (West Chester PA) Schoemaker ; Hubert J. P. (Newton MA), Immunoassay utilizing monoclonal high affinity IgM antibodies.
McCarthy James R. (West Chester OH) Barney Charlotte L. (Cincinnati OH) Matthews Donald P. (West Chester OH) Bey Philippe (Cincinnati OH), Inhibitors of lysyl oxidase.
Evans,Mark J.; Scicchitano,Marshall S.; Bapat,Ashok R.; Bhat,Ramesh A.; Mastroeni,Robert; Karathanasis,Sotirios K., Member of the lysyl oxidase gene family.
Evans,Mark J.; Scicchitano,Marshall S.; Bapat,Ashok R.; Bhat,Ramesh A.; Mastroeni,Robert; Karathanasis,Sotirios K., Member of the lysyl oxidase gene family.
Smulson Mark E. (Washington DC) Bhatia Kishor (Arbutus MD) Huppi Konrad (Reston VA), Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for hu.
Kim, Byung chul; Kim, Jhin gook; Hur, Nam; Lee, Kyu sang; Son, Dae soon; Park, Kyung hee; Ahn, Tae jin, Method of predicting risk of lung cancer recurrence, and a composition, kit and microarray for the same.
Hung Mien-Chie (Houston TX) Yu Di-Hua (Houston TX) Matin Angabin (Houston TX), Methods for the suppression of neu mediated tumors by adenoviral E1A and SV40 large T antigen.
Simonsson Leif R. (Hisings Backa SEX) Arielly Salo (Kungsbacka SEX) Aurell Leif E. (SrSEX) Claeson Karl G. (Linding SEX), Peptide substrates for determination of protease activity.
Surani Azim M. (Cambridge GB3) Neuberger Michael S. (Cambridge GB3) Bruggemann Marianne (Cambridge GB3), Production of antibodies from transgenic animals.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Cox, III, George Norbert; Case, Casey Christopher; Eisenberg, Stephen P.; Jarvis, Eric Edward; Spratt, Sharon Kaye, Regulation of endogenous gene expression in cells using zinc finger proteins.
Griss ; deceased Gerhart (late of Biberach DEX by Elisabeth Griss ; legal representative) Hurnaus Rudolf (Biberach DEX) Kobinger Walter (Vienna ATX) Pichler Ludwig (Vienna ATX) Bauer Rudolf (Wiesbade, Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals.
Griss ; deceased Gerhart (late of Biberach DEX by Elisabeth Griss ; legal representative) Schneider Claus (Ingelheim am Rhein DEX) Hurnaus Rudolf (Biberach DEX) Kobinger Walter (Vienna ATX) Pichler L, Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals.
Griss ; deceased Gerhart (late of Biberach DEX by Elisabeth Griss ; legal representative) Schneider Claus (Ingelheim am Rhein DEX) Hurnaus Rudolf (Biberach DEX) Kobinger Walter (Vienna ATX) Pichler L, Tetrahydro-benzthiazoles, the preparation thereof and their use as intermediate products or as pharmaceuticals.
Lonberg Nils (San Francisco CA) Kay Robert M. (San Francisco CA), Transgenic non-human animals capable of producing heterologous antibodies of various isotypes.
Smith, Victoria; Ogg, Scott; Van Vlasselaer, Peter; Barry, Vivian E.; Marshall, Derek; Holzer, Alison Kay; Rodriguez, Hector; Oyasu, Miho; McCauley, Scott Alan; Garcia, Carlos Aurelio; Biermann, Donna Hiroko Tokuoka, Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis.
Smith, Victoria; Ogg, Scott; Van Vlasselaer, Peter; Barry, Vivian E.; Marshall, Derek; Holzer, Alison Kay; Rodriguez, Hector; Oyasu, Miho; McCauley, Scott Alan; Garcia, Carlos Aurelio; Biermann, Donna Hiroko Tokuoka, Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis.
Neufeld, Gera; Akiri, Gal; Vadasz, Zahava; Gengrinovitch, Stela, Pharmaceutical compositions and methods useful for modulating angiogenesis, inhibiting metastasis and tumor fibrosis, and assessing the malignancy of colon cancer tumors.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.